BioStem Technologies, Inc. (BSEM)
OTCMKTS
· Delayed Price · Currency is USD
14.95
+0.29 (1.98%)
Jan 29, 2025, 4:00 PM EST
BioStem Technologies Revenue
BioStem Technologies had revenue of $82.56M in the quarter ending September 30, 2024, with 2,258.93% growth. This brings the company's revenue in the last twelve months to $210.49M, up 3,445.26% year-over-year. In the year 2023, BioStem Technologies had annual revenue of $16.69M with 142.69% growth.
Revenue (ttm)
210.49M
Revenue Growth
+3,445.26%
P/S Ratio
1.14
Revenue / Employee
6.38M
Employees
33
Market Cap
248.98M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 16.69M | 9.81M | 142.69% |
Dec 31, 2022 | 6.88M | 2.53M | 58.38% |
Dec 31, 2021 | 4.34M | 4.03M | 1,284.88% |
Dec 31, 2017 | 313.45K | -293.78K | -48.38% |
Dec 31, 2016 | 607.22K | 455.69K | 300.71% |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Dec 31, 2011 | Pro | Pro | Pro |
Dec 31, 2010 | Pro | Pro | Pro |
Dec 31, 2009 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
Veradigm | 1.53B |
SS Innovations International | 16.04M |
Elite Pharmaceuticals | 71.17M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 21.77M |
SANUWAVE Health | 29.30M |
BioStem Technologies News
- 21 days ago - BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje® - GlobeNewsWire
- 27 days ago - BioStem Technologies CEO to Present at Biotech Showcase 2025 - GlobeNewsWire
- 2 months ago - BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts - GlobeNewsWire
- 2 months ago - BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global - GlobeNewsWire
- 2 months ago - Long-Term, BioStem Technologies Still A Promising Growth Stock - Seeking Alpha
- 2 months ago - BioStem Technologies, Inc. (BSEM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions - GlobeNewsWire
- 3 months ago - BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT - Newsfile Corp